参考文献:1. Yuliantie, E. et al. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochem Pharmacol177, 114001 (2020).2. Cho, Y.M., Merchant, C.E. & Kieffer, T.J. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther135, 247-78 (2012).3. Gault, V.A., Flatt, P.R. & O’Harte, F.P.M. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun308, 207-213 (2003).4. Brown, J.C. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can J Biochem49, 255-61 (1971).5. Baggio, L.L. & Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology132, 2131-57 (2007).6. Christensen, M., Vedtofte, L., Holst, J.J., Vilsboll, T. & Knop, F.K. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes60, 3103-9 (2011).7. Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab18, 3-14 (2018).8. Siu, F.Y. et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature499, 444-9 (2013).9. Song, G. et al. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature546, 312-315 (2017).10. Sun, W. et al. A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor. Cell Res30, 1098-1108 (2020). —END—